Search

The Balearic Biotechnology and Biomedical Cluster (BIOIB) is leading a pioneering study in Spain on the impact of public affairs on this sector’s development and its social legitimization.

CONNECTA Therapeutics has achieved positive results in the Phase I clinical trial of CTH120, an investigational drug that modulates neuroplasticity to treat neurodevelopmental disorders such as

Expertos líderes en psiquiatría en EE.UU. se unen al Comité Asesor Clínico (CAC) de Oryzon para avanzar en el desarrollo de la Fase III de vafidemstat en Trastorno Límite de la Personalidad (TLP).

Pharmaron accelerates drug discovery by transforming scientific breakthroughs into therapies, using advanced technologies and a global team of 8,500+ chemists. They specialize in small molecules

Se han realizado inversiones en I+D por importe de 8,3 M€, de las cuales 7,6 M€ corresponden a desarrollo y 0,7 M€ a investigación. Tras la finalización del ensayo clínico PORTICO, la intensidad en

CENER reaffirms its commitment to innovation and sustainability through the BIOOLE-UP research and development project, positioning itself as a benchmark in biorefinery applied to global social

Despite advances in biotechnology and research, the lack of specialists, scarcity of treatments, and inequality in access to medical services remain crucial challenges for patients and their families.

The possibilities are certainly immense, but they require sustained R&D efforts and an environment that facilitates such developments.

According to the INE report, if we exclusively analyze the figure for companies, we observe that R&D investment increased by 5% compared to 2021. In 2022, the figure stood at 1.223 billion euros

BLUEREMEDIOMICS is expected to facilitate increased aquaculture production under more efficient food production and reduced environmental footprint scenarios.

The increasing complexity of clinical trials and evolving regulatory requirements pose significant challenges for Sponsors, CROs and Research Entities.

The initiative is coming to an end after three years of activity (2022-2024), accompanying the growth of eleven entities in the healthcare sector.

Miramoon Pharma has hit a major milestone with the publication of preclinical data for its two lead candidates in top-tier peer-reviewed journals.

The SEBBM, in collaboration with the Carmen and Severo Ochoa Foundation, launch the Severo Ochoa Conferences, which will deal monographically with research topics on the frontier of knowledge and will

BCN HEALTH has published 10 studies in 2024 that assess the incidence, productivity loss, and cost of disease for different diseases in Spain.

Meet Biointaxis, our new member. We spoke with Antoni Matilla Dueñas CEO, Co-fundador.

Integra Therapeutics has developed the FiCAT gene-writing platform to develop cell therapies for autoimmune and oncology diseases and gene therapies for rare diseases. The company recently announced a

To contribute to the democratization of access to new cell therapies, Klinea works on various initiatives. The project explained below is an example of this commitment.